{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:17:57Z","timestamp":1794331077549,"version":"4.9.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ygyno.2024.01.028","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:13:36Z","timestamp":1710548016000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Blair","family":"McNamara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Demirkiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias Max Philipp","family":"Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Manavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Mutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Zipponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang-Hartwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Pachter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.01.028_bb0005","article-title":"Trends of low-grade serous ovarian carcinoma in the United States","volume":"29","author":"Matsuo","year":"2018","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0010","doi-asserted-by":"crossref","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0015","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e4","article-title":"The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer","volume":"30","author":"Bogani","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2019.12.033","article-title":"Low-grade serous ovarian cancer: state of the science","volume":"156","author":"Slomovitz","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01164","article-title":"MILO\/ENGOT-ov11: Binimetinib versus Physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum","volume":"38","author":"Monk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0055","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-0621","article-title":"Molecular results and potential biomarkers identified from the phase 3 MILO\/ENGOT-ov11 study of Binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian Cancer","author":"Grisham","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2024.01.028_bb0065","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of raf activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective mek inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2024.01.028_bb0075","volume":"11","author":"Dual RAF-MEK Inhibitor Assessed","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30464-2","article-title":"Intermittent schedules of the oral RAF\u2013MEK inhibitor CH5126766\/VS-6766 in patients with RAS\/RAF-mutant solid tumours and multiple myeloma: a single-Centre, open-label, phase 1 dose-escalation and basket dose-expansion study","volume":"21","author":"Guo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26144250","article-title":"Drug discovery targeting focal adhesion kinase (Fak) as a promising cancer therapy","volume":"26","author":"Pang","year":"2021","journal-title":"Molecules."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0090","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ygyno.2024.01.028_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/bts236","article-title":"Xenome-a tool for classifying reads from xenograft samples","volume":"28","author":"Conway","year":"2012","journal-title":"Bioinformatics."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03056-x","article-title":"\u03b22-AR blockade potentiates MEK1\/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism","volume":"11","author":"Mele","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0105","article-title":"Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment","volume":"25","author":"Han","year":"2018","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2024.01.028_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","article-title":"Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766) \u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)","volume":"41","author":"Banerjee","year":"2023","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582400043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T11:05:29Z","timestamp":1717499129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582400043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":22,"alternative-id":["S009082582400043X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}